Stephane Hunot

List of Publications by Year
in descending order

58 papers	16,441 citations	76326 40 h-index	123424 61 g-index
61 all docs	61 docs citations	61 times ranked	20452 citing authors

#	Article	IF	Citations
1	Modelling Î±-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons. Cells, 2022, 11, 1640.	4.1	8
2	Editorial: Brain-Targeted Autoimmunity: Beyond Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 677577.	4.8	3
3	Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. Cell Death and Differentiation, 2019, 26, 580-596.	11.2	53
4	Effect of Vitamin D in HN9.10e Embryonic Hippocampal Cells and in Hippocampus from MPTP-Induced Parkinsonâ€™s Disease Mouse Model. Frontiers in Cellular Neuroscience, 2018, 12, 31.	3.7	16
5	Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. Journal of Neuroinflammation, 2017, 14, 60.	7.2	50
6	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain, 2017, 140, 184-200.	7.6	184
7	Legionella pneumophila Strain 130b Evades Macrophage Cell Death Independent of the Effector SidF in the Absence of Flagellin. Frontiers in Cellular and Infection Microbiology, 2017, 7, 35.	3.9	18
8	Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinsonâ€™s Disease and in Embryonic Hippocampal Cells. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	19
9	e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease. Mediators of Inflammation, 2016, 2016, 1-7.	3.0	12
10	Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. Neuron, 2016, 90, 675-691.	8.1	460
11	Adaptive preconditioning in neurological diseases â€“ therapeutic insights from proteostatic perturbations. Brain Research, 2016, 1648, 603-616.	2.2	41
12	Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	10.2	393
13	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	10.2	4,129
14	A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinsonâ€™s disease. Nature Communications, 2014, 5, 5181.	12.8	44
15	Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease. Journal of Neuroinflammation, 2014, 11, 86.	7.2	33
16	DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinsonâ€™s disease. Journal of Neuroinflammation, 2013, 10, 82.	7.2	11
17	MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson's disease. Neurobiology of Disease, 2013, 51, 192-201.	4.4	9
18	Effects of oral administration of rotenone on gastrointestinal functions in mice. Neurogastroenterology and Motility, 2013, 25, e183-93.	3.0	66

#	ARTICLE	IF	CITATIONS
19	Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Scientific Reports, 2013, 3, 1393.	3.3	134
20	Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Induces Astrocyte Proliferation through the Activation of Transforming-Growth Factor-Î±/Epidermal Growth Factor Receptor Signaling Pathway. Molecular Pharmacology, 2012, 82, 948-957.	2.3	15
21	Neuroinflammation in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S210-S212.	2.2	516
22	Inflammation and Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	1.1	9
23	Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. Journal of Neurochemistry, 2011, 118, 680-694.	3.9	115
24	Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6632-6637.	7.1	184
25	Editorial. Journal of Neural Transmission, 2010, 117, 897-898.	2.8	3
26	Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. Journal of Clinical Investigation, 2010, 120, 2745-2754.	8.2	359
27	Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Journal of Clinical Investigation, 2009, 119, 182-92.	8.2	875
28	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurology, The, 2009, 8, 382-397.	10.2	1,648
29	Pleiotrophin receptor RPTPâ€Î¶/Î² expression is upâ€regulated by <scp>l</scp>â€DOPA in striatal medium spiny neurons of parkinsonian rats. Journal of Neurochemistry, 2008, 107, 443-452.	3.9	22
30	Modelling Parkinsonâ€like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. Journal of Neurochemistry, 2008, 107, 701-711.	3.9	67
31	Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18578-18583.	7.1	354
32	The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3585-3590.	7.1	245
33	Neuroinflammatory processes in Parkinson's disease. Parkinsonism and Related Disorders, 2005, 11, S9-S15.	2.2	181
34	JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 665-670.	7.1	396
35	Neuroinflammatory processes in Parkinson's disease. Annals of Neurology, 2003, 53, S49-S60.	5.3	353
36	Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Experimental Neurology, 2003, 184, 561-564.	4.1	57

#	Article	IF	Citations
37	Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5473-5478.	7.1	611
38	The Role of Glial Reaction and Inflammation in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 214-228.	3.8	394
39	Role of TNF-Î± Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP. Experimental Neurology, 2002, 177, 183-192.	4.1	81
40	Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. Journal of Neurochemistry, 2002, 83, 320-330.	3.9	111
41	Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis. Journal of Neuroscience, 2001, 21, 2247-2255.	3.6	242
42	The inflammatory response in the Parkinson brain. Clinical Neuroscience Research, 2001, 1, 434-443.	0.8	37
43	APOPTOSIS: Death of a Monopoly?. Science, 2001, 292, 865-866.	12.6	62
44	Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nature Medicine, 2000, 6, 1241-1247.	30.7	303
45	Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2875-2880.	7.1	644
46	Nitric oxide, glial cells and neuronal degeneration in parkinsonism. Trends in Pharmacological Sciences, 2000, 21, 163-165.	8.7	54
47	Caspase knockouts: matters of life and death. Cell Death and Differentiation, 1999, 6, 1043-1053.	11.2	269
48	Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Movement Disorders, 1999, 14, 383-384.	3.9	147
49	An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience, 1999, 88, 1015-1032.	2.3	166
50	FcÎµRII/CD23 Is Expressed in Parkinsonâ€™s Disease and Induces,<i>In Vitro,</i>Production of Nitric Oxide and Tumor Necrosis Factor-Î± in Glial Cells. Journal of Neuroscience, 1999, 19, 3440-3447.	3.6	399
51	Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Advances in Neurology, 1999, 80, 9-18.	0.8	30
52	CD95 (APO-1/Fas) and Parkinson's disease. Annals of Neurology, 1998, 44, 425-425.	5.3	6
53	Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?. Annals of Neurology, 1998, 44, S115-20.	5.3	289
54	Nuclear translocation of NF-ÎºB in cholinergic neurons of patients with AlzheimerÊ¼s disease. NeuroReport, 1997, 8, 2849-2852.	1.2	147

#	Article	IF	Citations
55	Nuclear translocation of NF-ÂB is increased in dopaminergic neurons of patients with Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7531-7536.	7.1	657
56	Trk Neurotrophin Receptors in Cholinergic Neurons of Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1997, 8, 1-8.	1.5	36
57	Nitric oxide synthase and neuronal vulnerability in parkinson's disease. Neuroscience, 1996, 72, 355-363.	2.3	556
58	Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: A post mortem in situ hybridization study with special reference to Parkinson's disease. Journal of Neural Transmission, 1996, 103, 1043-1052.	2.8	84